Randomized trial data support the use of either TNF or IL-17 inhibitors to treat axial spondyloarthritis, based on patient ...

Everyone’s experience with axSpA is different, but these real-life strategies show there are multiple ways to find relief when pain hits.

Multiple TNF inhibitors, as well as interleukin-17 blockers such as secukinumab (Cosentyx) and Janus kinase (JAK) inhibitors ...

UCB, a global biopharmaceutical company, today announced new three-year data from Phase 3 trials, and their open-label extensions, investigating BIMZELX (R) (bimekizumab-bkzx) in adults with active ...

UCB, a global biopharmaceutical company, today announced new three-year data from Phase 3 trials, and their open-label extensions, investigating BIMZELX® (bimekizumab-bkzx) in adults with active ...

Upadacitinib treatment was associated with reduced non-nociceptive pain among patients with axSpA, including both neuropathic and nociplastic types.

An Indian researcher at Yale has developed the A-tool, a simple online questionnaire to help detect axial spondyloarthritis, a chronic back pain condi ...

For millions of people living with back pain, the cause is often elusive. One underrecognized culprit is axial ...

MRI scans may be useful to monitor disease activity and detect active inflammation in axial spondyloarthritis, with the results influencing clinical decisions.

The FDA has granted breakthrough device designation to Augurex’s SPINEstat 14-3-3eta Autoantibody Multiplex Immunoassay Test.

Ended the third quarter with $380.5 million in cash, cash equivalents and short-term marketable debt securities which, together with funds from a ...

Augurex Life Sciences Corp., a leader in the development of autoimmune diagnostic tests, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to ...